Literature DB >> 9924639

Airway responsiveness to inhaled albuterol in patients with pulmonary hypertension.

A R O'Hagan1, P C Stillwell, A Arroliga.   

Abstract

We studied patients with pulmonary hypertension who had evidence of bronchial responsiveness to inhaled albuterol. The records of all patients evaluated for lung transplantation were reviewed: the charts of patients with pulmonary hypertension, either primary (PPH, n = 46) or Eisenmenger's syndrome (n = 12), were abstracted. Measurements of lung function revealed equal numbers of patients with normal, restrictive, obstructive, and mixed abnormalities. None were more than moderate. Airway responsiveness was defined as an increase of forced expiratory volume in 1 second (FEV1) > 15% or forced expiratory flow between 25% and 75% of the vital capacity (FEF25-75) > 25%. Of the 24 PPH and nine Eisenmenger's patients, 14 and four, respectively, had reversible airflow obstruction. These patients were more likely to have a history of atopic disease and to have responded to calcium channels blockers during hemodynamic monitoring. They did not have more severe pulmonary hypertension, as measured by hemodynamic monitoring. Four patients had a history of asthma, which required hospitalization in three. Reversible airflow obstruction occurred in half of the patients with pulmonary hypertension and was clinically important in at least three.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9924639     DOI: 10.1177/000992289903800104

Source DB:  PubMed          Journal:  Clin Pediatr (Phila)        ISSN: 0009-9228            Impact factor:   1.168


  4 in total

1.  Peripheral airway obstruction in primary pulmonary hypertension.

Authors:  F J Meyer; R Ewert; M M Hoeper; H Olschewski; J Behr; J Winkler; H Wilkens; C Breuer; W Kübler; M M Borst
Journal:  Thorax       Date:  2002-06       Impact factor: 9.139

2.  Double Trouble: Airflow and Pulmonary Vascular Obstruction.

Authors:  Michael H Lee; Brian B Graham; Todd M Bull
Journal:  Am J Respir Crit Care Med       Date:  2021-12-15       Impact factor: 21.405

3.  Endothelin receptor antagonist and airway dysfunction in pulmonary arterial hypertension.

Authors:  Annette S Droste; David Rohde; Mirko Voelkers; Arthur Filusch; Thomas Bruckner; Mathias M Borst; Hugo A Katus; F Joachim Meyer
Journal:  Respir Res       Date:  2009-12-30

4.  Loss of alveolar membrane diffusing capacity and pulmonary capillary blood volume in pulmonary arterial hypertension.

Authors:  Samar Farha; Daniel Laskowski; Deepa George; Margaret M Park; W H Wilson Tang; Raed A Dweik; Serpil C Erzurum
Journal:  Respir Res       Date:  2013-01-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.